Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 14/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
| ▸ | TXK | P42681 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638466 | 0.92 | AKT3 (0.62) | AKT3TECTXKBTKITK | |
| SCHEMBL3471170 | 0.88 | AKT3 (0.55) | AKT3ESRRGHDAC1CYP3A4DYRK1A | |
| SCHEMBL13638295 | 0.86 | AKT3 (0.38) | AKT3TECTXKBTKITK | |
| SCHEMBL13638465 | 0.86 | HPGDS (0.47) | AKT3TECTXKBTKITK | |
| SCHEMBL13638504 | 0.85 | AKT3 (0.48) | AKT3TECTXKBTKITK | |
| SCHEMBL13638565 | 0.85 | AKT3 (0.48) | AKT3TECTXKBTKITK | |
| SCHEMBL14612850 | 0.83 | AKT3 (0.37) | AKT3TECTXKBTKITK | |
| SCHEMBL13638669 | 0.82 | CDK2 (0.36) | AKT3TECTXKBTKITK | |
| SCHEMBL13638569 | 0.82 | AKT3 (0.37) | AKT3TECTXKBTKITK | |
| SCHEMBL13638571 | 0.81 | AKT3 (0.40) | AKT3TECTXKBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | AKT3 678/4885ESRRG 4721/4885TEC 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.